Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
12
×
boston top stories
deals
12
×
life sciences
national blog main
national top stories
roche
12
×
biotech
san francisco blog main
san francisco top stories
cancer
clinical trials
fda
investing
new york blog main
detroit blog main
detroit top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
indiana blog main
indiana top stories
national
takeda pharmaceutical
alzheimer's disease
amgen
biogen
What
drug
roundup
bio
roche
cancer
fda
gene
medicines
ahead
approval
asco
big
billion
companies
crispr
days
medicine
patients
pay
recently
research
startup
team
therapeutics
today
acquire
acquisitions
admits
ago
agreed
albert
alliance
alzheimer’s
ambien
american
analytics
annual
attendees
attention
betting
Language
unset
unknown
Current search:
deals
×
roche
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
6 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More